---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000355"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-09-27T23:59:59+00:00"
generated_at: "2026-06-29T01:17:20.816754+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma receives USPTO Notice of Allowance for NR2F6 activity modulators patent

## Summary
- Notice of Allowance issued Sept 23, 2021 for patent on small molecule agonists/antagonists of NR2F6.
- Invention relates to compounds that alter NR2F6 activity, a nuclear receptor involved in immune regulation.
- Allowed patent strengthens Regen's IP position for its small molecule immunomodulator program.

## SEC filing metadata
- accession: 0001607062-21-000355
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000355/0001607062-21-000355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000355/rgbp092721form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000355
- JSON: https://secwatch.observer/filing/0001607062-21-000355.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.